Mycophenolate Mofetil and Risk of Developing Malignancy After Orthotopic Heart Transplantation: Analysis of the Transplant Registry of the International Society for Heart and Lung Transplantation

Journal of Heart and Lung Transplantation

Volumn 25, Issue 10, 2006, Pages 1186-1191

  O'Neill, James O ^a   Edwards, Leah B ^a   Taylor, David O ^a  

^a International Society for Heart and Lung Transplantation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; AGED; ARTICLE; CANCER RISK; CARDIAC GRAFT REJECTION; COHORT ANALYSIS; CONFIDENCE INTERVAL; FEMALE; FOLLOW UP; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; REGISTER; SKIN CANCER; SKIN TUMOR; UNIVARIATE ANALYSIS;

AGING; COHORT STUDIES; FEMALE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERNATIONALITY; LUNG TRANSPLANTATION; MALE; MEDICAL RECORDS; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYCOPHENOLIC ACID; NEOPLASMS; REGISTRIES; RISK; SEX FACTORS; SOCIETIES, MEDICAL;

EID: 33749507195     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2006.06.010     Document Type: Article

References (15)

1. Penn I., Hammond W., Bretschneider L., and Starzl T.E. Malignant lymphomas in transplantation patients. Transplant Proc 1 (1969) 106-112
2. Penn I. The price of immunotherapy. Curr Probl Surg 18 (1981) 681-751
3. Penn I. Posttransplant malignancies. Transplant Proc 31 (1999) 1260-1262
4. Hunt S.A. Malignancy in organ transplantation: heart. Transplant Proc 34 (2002) 1874-1876
5. Penn I. The effect of immunosuppression on pre-existing cancers. Transplantation 55 (1993) 742-747
6. Penn I. Effect of immunosuppression on preexisting cancers. Transplant Proc 25 (1993) 1380-1382
7. Ippoliti G., Rinaldi M., Pellegrini C., and Vigano M. Incidence of cancer after immunosuppressive treatment for heart transplantation. Crit Rev Oncol/Hematol 56 (2005) 101-113
8. Haupton P., and Medra M.R. It is time to stop ignoring malignancy in heart transplantation: a call to arms. J Heart Lung Transplant 24 (2005) 1111-1113
9. Buell J.F., Papaconstantinou H.T., Skalow B., Hanaway M.J., Alloway R.R., and Woodle E.S. De novo colorectal cancer: five-year survival is markedly lower in transplant recipients compared with the general population. Transplant Proc 37 (2005) 960-961
10. Taylor D.O., Edwards L.B., Mohacsi P.J., et al. The registry of the International Society for Heart and Lung Transplantation: twentieth official adult heart transplant report-2003. J Heart Lung Transplant 22 (2003) 616-624
11. Keogh A. Long-term benefits of mycophenolate mofetil after heart transplantation. Transplantation 79 suppl (2005) S45-S46
12. deSalvo T.G., Naftel D.C., Kasper E.K., et al. The differing hazard of lymphoma vs. other malignancies in the current era. J Heart Lung Transplant 17 (1998) 70
13. Opelz G. Are post-transplant lymphomas inevitable?. Nephrol Dial Transplant 11 (1996) 1952-1955
14. Mancini D., Pinney S., Burkhoff D., et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 108 (2003) 48-53
15. Eisen H.J., Kowabashiga J., Keogh A., et al. Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. J Heart Lung Transplant 24 (2005) 517-525